Ascentage Pharma Group International (OTCMKTS:ASPHF – Get Free Report)’s stock price fell 23.4% on Tuesday . The company traded as low as $7.50 and last traded at $7.7350. 3,556 shares were traded during mid-day trading, a decline of 15% from the average session volume of 4,200 shares. The stock had previously closed at $10.10.
Ascentage Pharma Group International Stock Down 23.4%
The stock has a fifty day moving average of $9.26 and a 200-day moving average of $7.75.
Ascentage Pharma Group International Company Profile
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation.
Recommended Stories
- Five stocks we like better than Ascentage Pharma Group International
- Why Are These Companies Considered Blue Chips?
- Warner Bros. Sale Rumors Heat Up: What Investors Need to Know
- Business Services Stocks Investing
- From Science Project to Solvent: WeRide’s 761% Revenue Surge
- What Do S&P 500 Stocks Tell Investors About the Market?
- Will the S&P 500 Rally in December? These 3 Signals Point to a Big Move Ahead
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
